JPMorgan Chase & Co. Has $765,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

JPMorgan Chase & Co. raised its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 221.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,660 shares of the company's stock after buying an additional 67,325 shares during the period. JPMorgan Chase & Co. owned 0.22% of Y-mAbs Therapeutics worth $765,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company's stock worth $910,000 after acquiring an additional 56,244 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after purchasing an additional 47,846 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Y-mAbs Therapeutics by 6,911.6% in the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company's stock valued at $212,000 after purchasing an additional 26,748 shares in the last quarter. Principal Financial Group Inc. bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $267,000. Finally, KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $46,000. 70.85% of the stock is owned by institutional investors.

Analyst Ratings Changes

YMAB has been the subject of several research reports. Wedbush reissued an "outperform" rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Tuesday, April 22nd. HC Wainwright cut their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Morgan Stanley reduced their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Finally, Truist Financial dropped their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.40.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.50% of the company's stock.

Y-mAbs Therapeutics Stock Down 3.3 %

Y-mAbs Therapeutics stock traded down $0.14 during mid-day trading on Thursday, hitting $4.11. 203,869 shares of the company's stock were exchanged, compared to its average volume of 326,749. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $17.78. The firm has a market capitalization of $185.85 million, a P/E ratio of -7.61 and a beta of 0.71. The company's 50 day simple moving average is $4.76 and its 200-day simple moving average is $7.98.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same period in the prior year, the business earned ($0.02) EPS. Research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.